IL1RAP
Interleukin-1 receptor accessory protein
As of the edition of 20 October 2026, IL1RAP (interleukin-1 receptor accessory protein, UniProt Q9NPH3) has 2 drugs tested at it and 3 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NPH3
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 4
- Disease areas
- Skin and connective tissue; Lungs and airways; Immune system; Inherited and neonatal; Infections
- Registered trials of its drugs
- 17
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Astegolimab | Active | Phase 3 | none listed |
| Imsidolimab | Stopped | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 3 |
| Total on the list | 3 |